Biopharmaceutical Excipients Market To Reach $4.97 Billion By 2033

Biopharmaceutical Excipients Market Growth & Trends

The global biopharmaceutical excipients market size is estimated to reach USD 4.97 billion by 2033, registering a CAGR of 5.79% from 2026 to 2033, according to a new report by Grand View Research, Inc. The increasing focus of pharmaceutical players on the generic market, rising adoption of multifunctional excipients, and patent expiry of biological actives are the key factors propelling market growth. Furthermore, the cost-efficiency & competency of manufacturers and the chemical and physical instability of biopharmaceuticals are boosting the development of excipients, thus propelling the market.

The demand for biosimilars has increased in recent years, which has in turn led to a rise in the demand for biopharmaceutical excipients. Supporting factors such as patent expirations, increasing government funding, patient demographics, and rising affordability have propelled the adoption of biosimilars across the globe. In addition, the rapidly evolving healthcare infrastructure in developing economies has increased their use in the production of biogenerics. Furthermore, the introduction of well-framed legislation to ensure proper regulatory and testing standards for biosimilars globally is set to ease market entry for manufacturers.

Moreover, the growing acceptance of multi-functional biopharmaceutical excipients in industries is also driving market growth. They are efficient and effective in enhancing the manufacturing process for biopharmaceuticals. Associated advantages include better product quality, improved productivity, and reduced operating costs. The success of COVID-19 vaccines majorly relies on their efficiency, which has been enhanced by using efficient drug delivery systems; this offers immense lucrative opportunities for market entities.

Key operating players in the market are focusing on the development and launch of novel biopharmaceutical excipients. For instance, in April 2021, DFE Pharma introduced a new excipient product line ‘BioHale’ to address global supply challenges for biopharmaceutical companies. Furthermore, the geographical expansion of manufacturing facilities is increasing, owing to the rising demand for biopharmaceutical excipients. For instance, in May 2022, DFE Pharma opened a new facility in India to offer fast-track formulation services, including excipients, for pharmaceutical players to achieve the right formulations.

However, issues pertaining to the supply chain in the biopharmaceutical industry and challenges in the development of excipients for biologics are expected to hamper the market during the forecast period. Selecting the right excipient for biopharmaceuticals is a challenging and complicated task, as an excipient effective in one formulation may cause degradation or aggregation of the protein in another. A limited number of known & approved products for the stabilization of protein further increases challenges for biopharma manufacturers. Hence, to deal with these challenges, researchers are developing new and innovative approaches. For instance, to maintain the stability of lipid-based excipients (HMC excipients), researchers have applied polyglycerol esters of fatty acids (PGFAs). Currently, these products are witnessing an increasing demand for the development of COVID-19 vaccines.

 Request a free sample copy or view report summary: Biopharmaceutical Excipients Market Report

Biopharmaceutical Excipients Market Report Highlights

• Based on product, the solubilizes & surfactants/emulsifiers segment held the largest revenue share of 37.25% in 2025, driven by their critical role in maintaining the stability and performance of complex biopharmaceutical formulations.

• Based on material, the sugars & polyols segment held the largest revenue share of 35.91% in 2025, due to the rapid expansion of biologics such as monoclonal antibodies, recombinant proteins, vaccines, and peptides.

• Based on dosage form, the parenteral (liquid injectables) segment held the largest revenue share of 60.43% in 2025, due to its critical role in the administration of biologics such as monoclonal antibodies, vaccines, and gene therapies that require direct delivery into the bloodstream for rapid and controlled therapeutic effect.

• Based on therapeutical modality, the monoclonal antibodies segment held the largest revenue share of 45.64% in 2025, due to their widespread clinical adoption across multiple therapeutic areas and the increasing complexity of their formulations.

• The North America dominated the global biopharmaceutical excipients market with the largest market share of 33.96% in 2025 due to the strong concentration of biologic drug developers and contract manufacturing organizations.

Biopharmaceutical Excipients Market Segmentation

Grand View Research has segmented the global biopharmaceutical excipients market based on product, material, dosage form, therapeutic modality, and region:

Biopharmaceutical Excipients Product Outlook (Revenue, USD Million, 2021 - 2033)

• Solubilizes & Surfactants/Emulsifiers      

  • Triglycerides

  • Esters

  • Others

• Polyols 

  • Mannitol

  • Sorbitol

  • Others

• Carbohydrates 

  • Sucrose

  • Dextrose

  • Starch

  • Others

• Specialty Excipients

Biopharmaceutical Excipients Material Outlook (Revenue, USD Million, 2021 - 2033)

• Sugars & Polyols

• Polymers

• Amino Acids

• Inorganic Salts & Buffers

• Specialty Co-Processed Excipients / Novel Excipients

Biopharmaceutical Excipients Dosage Form Outlook (Revenue, USD Million, 2021 - 2033)

• Parenteral (Liquid injectables)

• Lyophilized (Freeze-dried)

• Others

Biopharmaceutical Excipients Therapeutic Modality Outlook (Revenue, USD Million, 2021 - 2033)

• Monoclonal Antibodies

• Recombinant Proteins & Enzymes

• Vaccines

• Cell & Gene Therapy Formulations

• Peptides & Oligonucleotides

Biopharmaceutical Excipients Regional Outlook (Revenue, USD Million, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Biopharmaceutical Excipients Market

• Merck KGaA

• Colorcon

• BASF SE

• Associated British Foods plc

• Signet Excipients Pvt. Ltd (IMCD)

• Sigachi Industries Limited

• Spectrum Chemical Manufacturing Corp.

• Roquette Frères

• IMCD

• Clariant

• DFE Pharma

• J. RETTENMAIER & SÖHNE GmbH + Co KG

• Evonik Industries AG